- Clinical trial data for eteplirsen not enough for early/accelerated FDA approval is among the claims of research shop Favus in what Adam Feuerstein calls a "rehash of old short arguments."
- Sarepta Therapeutics (SRPT -8.4%).
- Not helping is a second straight day of big declines for momentum names in general and biotech stocks in particular.
Sarepta hit by new short attack; general biotech selloff
Oct 9 2013, 12:25 ET